Baidu
map

Cancer Discovery:患前列腺癌风险高不高?基因一测就知道

2015-04-07 Zhang JL译 MedSci原创

前列腺癌在一生中影响着每6人中的1人,是美国男性癌症死亡的第二个最常见的原因,导致在2015年估计有27500人死亡。早期识别有更高患前列腺癌的风险能够有效降低死亡率。Moffitt癌症中心的研究人员与来自世界各地的科学家所组成的一个研究小组,已经确定了22个基因变异,会增加患前列腺癌的风险。该研究结果发表在最新一期Cancer Discovery杂志上。有前列腺癌家族史的男性具有翻倍的患病风险。

前列腺癌在一生中影响着每6人中的1人,是美国男性癌症死亡的第二个最常见的原因,导致在2015年估计有27500人死亡。早期识别有更高患前列腺癌的风险能够有效降低死亡率。Moffitt癌症中心的研究人员与来自世界各地的科学家所组成的一个研究小组,已经确定了22个基因变异,会增加患前列腺癌的风险。该研究结果发表在最新一期Cancer Discovery杂志上。

有前列腺癌家族史的男性具有翻倍的患病风险。目前,已发现大约100个基因变异影响着患前列腺癌的风险。然而,这些变异只占使家庭性患病风险增加的33%,表明肯定存在额外的遗传因素。

Moffitt研究人员参加了一个名为PRACTICAL(调查癌症基因组改变的前列腺癌研究协作小组)的大型国际研究,该联盟的目标是识别与前列腺癌相关的遗传风险因素。他们比较了来自23个不同临床研究的22301例前列腺癌病例和22320例正常对照之间遗传信息的差异。该研究团队重点关注分析称为小分子核糖核酸(microRNAs)的遗传物质。

Moffitt癌症流行病学项目的准会员及分子流行病学家Jong Park博士解释说:“MicroRNAs是作为监控主管的小分子,能够通过与靶基因的特定区域结合来对多个癌症相关基因的表达进行控制。”

研究人员发现22种microRNA结合位点的变化,而这些变化正是影响患前列腺癌风险的因素。在这22种变异中,其中10种变异在过去的研究中并没有作为潜在的患癌风险因素而被深入研究。重要的是,其中7种变异可以区分激进和非激进性的疾病。

研究人员在正常和癌的前列腺组织中,通过检测两个基因变异对组织蛋白表达水平的影响,进一步证实了这两种遗传变异的重要性。他们发现的其中一个变异中在介导前列腺血清标志物PSA的表达中扮演一个重要的角色,而另一个变量则与控制参与新陈代谢基因的表达相关。

Park说:“我们希望通过本项研究的结果,最终促成研发出一种简单的基于基因型的血液检测,可用于与PSA和DRE检测联合以帮助医疗人员和病人准确预测疾病的风险。”这项研究的结果也可能帮助医生区分生长缓慢和侵袭性前列腺肿瘤,并有助于治疗决策。

原始出处:


S. Stegeman, E. Amankwah, K. Klein, T. A. O'Mara, D. Kim, H.-Y. Lin, J. Permuth-Wey, T. A. Sellers, S. Srinivasan, R. Eeles, D. Easton, Z. Kote-Jarai, A. A. Al Olama, S. Benlloch, K. Muir, G. G. Giles, F. Wiklund, H. Gronberg, C. A. Haiman, J. Schleutker, B. G. Nordestgaard, R. C. Travis, D. Neal, P. Pharoah, K.-T. Khaw, J. L. Stanford, W. J. Blot, S. Thibodeau, C. Maier, A. S. Kibel, C. Cybulski, L. Cannon-Albright, H. Brenner, R. Kaneva, M. R. Teixeira, A. B. Spurdle, J. A. Clements, J. Y. Park, J. Batra. A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discovery, 2015; DOI: 10.1158/2159-8290.CD-14-1057

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061458, encodeId=46d92061458fe, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Aug 13 15:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783681, encodeId=c52f1e836813e, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Feb 09 10:09:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011965, encodeId=50e72011965f8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Feb 14 04:09:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022544, encodeId=4e132022544fa, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Feb 17 19:09:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24737, encodeId=55c424e3714, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:52:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587779, encodeId=5181158e77968, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Apr 09 01:09:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19858, encodeId=bc1619858ff, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19859, encodeId=f4a219859ce, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19860, encodeId=94e31986009, content=不错的资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19861, encodeId=0a57198610e, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=)]
    2015-08-13 sjq027
  2. [GetPortalCommentsPageByObjectIdResponse(id=2061458, encodeId=46d92061458fe, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Aug 13 15:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783681, encodeId=c52f1e836813e, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Feb 09 10:09:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011965, encodeId=50e72011965f8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Feb 14 04:09:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022544, encodeId=4e132022544fa, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Feb 17 19:09:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24737, encodeId=55c424e3714, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:52:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587779, encodeId=5181158e77968, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Apr 09 01:09:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19858, encodeId=bc1619858ff, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19859, encodeId=f4a219859ce, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19860, encodeId=94e31986009, content=不错的资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19861, encodeId=0a57198610e, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=)]
    2016-02-09 yahu
  3. [GetPortalCommentsPageByObjectIdResponse(id=2061458, encodeId=46d92061458fe, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Aug 13 15:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783681, encodeId=c52f1e836813e, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Feb 09 10:09:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011965, encodeId=50e72011965f8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Feb 14 04:09:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022544, encodeId=4e132022544fa, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Feb 17 19:09:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24737, encodeId=55c424e3714, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:52:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587779, encodeId=5181158e77968, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Apr 09 01:09:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19858, encodeId=bc1619858ff, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19859, encodeId=f4a219859ce, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19860, encodeId=94e31986009, content=不错的资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19861, encodeId=0a57198610e, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2061458, encodeId=46d92061458fe, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Aug 13 15:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783681, encodeId=c52f1e836813e, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Feb 09 10:09:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011965, encodeId=50e72011965f8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Feb 14 04:09:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022544, encodeId=4e132022544fa, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Feb 17 19:09:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24737, encodeId=55c424e3714, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:52:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587779, encodeId=5181158e77968, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Apr 09 01:09:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19858, encodeId=bc1619858ff, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19859, encodeId=f4a219859ce, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19860, encodeId=94e31986009, content=不错的资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19861, encodeId=0a57198610e, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2061458, encodeId=46d92061458fe, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Aug 13 15:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783681, encodeId=c52f1e836813e, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Feb 09 10:09:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011965, encodeId=50e72011965f8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Feb 14 04:09:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022544, encodeId=4e132022544fa, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Feb 17 19:09:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24737, encodeId=55c424e3714, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:52:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587779, encodeId=5181158e77968, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Apr 09 01:09:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19858, encodeId=bc1619858ff, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19859, encodeId=f4a219859ce, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19860, encodeId=94e31986009, content=不错的资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19861, encodeId=0a57198610e, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=)]
    2015-05-24 ljjj1053

    不错,学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2061458, encodeId=46d92061458fe, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Aug 13 15:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783681, encodeId=c52f1e836813e, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Feb 09 10:09:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011965, encodeId=50e72011965f8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Feb 14 04:09:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022544, encodeId=4e132022544fa, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Feb 17 19:09:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24737, encodeId=55c424e3714, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:52:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587779, encodeId=5181158e77968, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Apr 09 01:09:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19858, encodeId=bc1619858ff, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19859, encodeId=f4a219859ce, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19860, encodeId=94e31986009, content=不错的资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19861, encodeId=0a57198610e, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=)]
    2015-04-09 yankaienglish
  7. [GetPortalCommentsPageByObjectIdResponse(id=2061458, encodeId=46d92061458fe, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Aug 13 15:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783681, encodeId=c52f1e836813e, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Feb 09 10:09:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011965, encodeId=50e72011965f8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Feb 14 04:09:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022544, encodeId=4e132022544fa, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Feb 17 19:09:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24737, encodeId=55c424e3714, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:52:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587779, encodeId=5181158e77968, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Apr 09 01:09:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19858, encodeId=bc1619858ff, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19859, encodeId=f4a219859ce, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19860, encodeId=94e31986009, content=不错的资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19861, encodeId=0a57198610e, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=)]
    2015-04-07 清氺訫

    值得学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2061458, encodeId=46d92061458fe, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Aug 13 15:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783681, encodeId=c52f1e836813e, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Feb 09 10:09:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011965, encodeId=50e72011965f8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Feb 14 04:09:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022544, encodeId=4e132022544fa, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Feb 17 19:09:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24737, encodeId=55c424e3714, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:52:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587779, encodeId=5181158e77968, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Apr 09 01:09:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19858, encodeId=bc1619858ff, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19859, encodeId=f4a219859ce, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19860, encodeId=94e31986009, content=不错的资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19861, encodeId=0a57198610e, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=)]
    2015-04-07 清氺訫

    有意义

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2061458, encodeId=46d92061458fe, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Aug 13 15:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783681, encodeId=c52f1e836813e, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Feb 09 10:09:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011965, encodeId=50e72011965f8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Feb 14 04:09:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022544, encodeId=4e132022544fa, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Feb 17 19:09:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24737, encodeId=55c424e3714, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:52:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587779, encodeId=5181158e77968, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Apr 09 01:09:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19858, encodeId=bc1619858ff, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19859, encodeId=f4a219859ce, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19860, encodeId=94e31986009, content=不错的资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19861, encodeId=0a57198610e, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=)]
    2015-04-07 清氺訫

    不错的资料

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2061458, encodeId=46d92061458fe, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Aug 13 15:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783681, encodeId=c52f1e836813e, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Feb 09 10:09:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011965, encodeId=50e72011965f8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Feb 14 04:09:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022544, encodeId=4e132022544fa, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Feb 17 19:09:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24737, encodeId=55c424e3714, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:52:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587779, encodeId=5181158e77968, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Apr 09 01:09:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19858, encodeId=bc1619858ff, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19859, encodeId=f4a219859ce, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19860, encodeId=94e31986009, content=不错的资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19861, encodeId=0a57198610e, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/28/a28e8ea268716dfc601012321847bccf.jpg, createdBy=e21a1620364, createdName=清氺訫, createdTime=Tue Apr 07 14:31:00 CST 2015, time=2015-04-07, status=1, ipAttribution=)]
    2015-04-07 清氺訫

    支持

    0

相关资讯

BJC:瑞典科学家发现预测前列腺癌转移新标记

近日,瑞典科学家在国际期刊British journal of cancer发表了他们关于Par6磷酸化影响前列腺癌迁移的最新研究进展。   PAR复合物主要包括par6,par3和非典型蛋白酶C(aPKC)等组成部分,该复合物对于细胞极化具有重要作用,而细胞极化过程缺失会促进癌症的发展。有研究发现TGFβ诱导的par6  345位丝氨酸磷酸化对于乳腺癌细胞发生上皮细胞向间

Nature:刨根问底——探索前列腺癌发展之路

根据发表在Nature杂志上的研究,科学家们已经揭示了男性个体前列腺癌的本质,指出尽管不同个体肿瘤中基因可能千差万别,但却万变不离其宗——存在着共同的基因缺陷,这一发现可以为日后发展新治疗方式提供希望。在这一具有里程碑意义的论文中,英国癌症研究中心资助的科学家与一个国际研究小组的研究人员共同通读了10例前列腺癌患者肿瘤样本的所有DNA。据此他们描绘了这一肿瘤在基因水平的 “家族树”变化,涵盖了在肿

Europ Urol:老年前列腺癌患者保守治疗效果可观?

新泽西州罗格斯大学癌症研究所以人群为基础的调查研究结果显示,低风险前列腺癌患者接受保守的治疗与管理能够获得良好的生存结果。研究的主要作者、新泽西癌症研究所的流行病学家及Rutgers Robert Wood Johnson医科大学教授Grace Lu-Yao博士,与其同事研究了该观察人群10年的结果 (JAMA,Vol. 302, No. 11)。这一项2009年的研究显示,这群早在1990年患有

Cancer Cell & Nat Med:喜人!新药可能对急性白血病和前列腺癌有效

来自密歇根大学综合癌症中心的研究人员在实验室研究中开发出一种能够治疗一种罕见类型的急性白血病的新药。另外的研究显示相同的化合物可能在前列腺癌的治疗中发挥作用。该复合物是由Jolanta Grembecka博士和Tomasz Cierpicki博士的实验室所开发的。该实验室在过去的多年研究中,主力研发一种小分子抑制剂,以阻止蛋白质menin和MLL融合蛋白之间相互作用,而后者则是导致一种罕见的急性白

Curr Opin Oncol:晚期前列腺癌多方面药物的组合以及排序治疗

评审目的:多个具有非常不同的作用机制和独特的毒副作用和功效的药物常常被用于晚期前列腺癌的治疗。下一波的研究重点是对当前可用的药物进行组合以及最优化的排序。本文的重点是提供过去一年临床晚期前列腺癌治疗的更新数据,指出正在进行研究的有前景的新靶点以及新化合物。 最近发现: 在转移性阉割抵抗的前列腺癌中,与安慰剂组相比,先于化疗的恩杂鲁胺的临床使用表明无进展生存期和总生存期有改善。恩杂鲁胺化疗抵抗的男

招募患者:Enzalutamide用于非转移去势难治前列腺癌患者的安全有效性临床研究

1. 试验药物简介 Enzalutamide (MDV3100)是一种雄激素受体(AR)拮抗剂,已于2012年获得FDA批准上市,用于治疗已扩散或复发的晚期(转移性)男性去势抵抗性前列腺癌。 2. 试验目的 通过评估无转移生存期(MFS)以确定MDV3100与安慰剂相比的有效性,并评价其在非转移性去势难治性前列腺癌患者中的获益及安全性。 3. 试

Baidu
map
Baidu
map
Baidu
map